Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.79 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3141804 | 0.89 | KCNH2 (0.62) | KCNH2SLC2A1 | |
| Hydrochloric Acid SCHEMBL3221024 | 0.88 | KCNH2 (0.61) | KCNH2SLC2A1 | |
| SCHEMBL2930373 | 0.88 | KCNH2 (1.00) | KCNH2SLC2A1TOP2A | |
| Hydrochloric Acid SCHEMBL2935717 | 0.88 | KCNH2 (0.98) | KCNH2SLC2A1TOP2A | |
| SCHEMBL2931798 | 0.86 | KCNH2 (0.80) | KCNH2SLC2A1TOP2A | |
| SCHEMBL4428334 | 0.84 | KCNH2 (0.56) | KCNH2SLC2A1 | |
| SCHEMBL3548269 | 0.83 | KCNH2 (0.81) | KCNH2SLC2A1TOP2A | |
| SCHEMBL3225945 | 0.83 | KCNH2 (0.55) | KCNH2SLC2A1 | |
| Hydrochloric Acid SCHEMBL3228092 | 0.83 | KCNH2 (0.54) | KCNH2SLC2A1 | |
| SCHEMBL2931641 | 0.81 | KCNH2 (0.88) | KCNH2SLC2A1TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001887-B1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2010-09-15 | — | — | EP | claimed |
| US-7709483-B2 | Pyrrolo-quinoxalinone derivatives as antibacterials | GLAXO GROUP LIMITED (GB) | 2010-05-04 | — | — | US | claimed |
| US-20090062265-A1 | Pyrrolo-Quinoxalinone Derivatives as Antibacterials | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | claimed |
| EP-2001887-A1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2008-12-17 | — | — | EP | claimed |
| WO-2007115947-A1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2007-10-18 | — | — | WO | claimed |
| EP-2001887-B1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2010-09-15 | — | — | EP | disclosed |
| EP-2001887-B1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2010-09-15 | — | — | EP | disclosed |
| US-7709483-B2 | Pyrrolo-quinoxalinone derivatives as antibacterials | GLAXO GROUP LIMITED (GB) | 2010-05-04 | — | — | US | disclosed |
| US-7709483-B2 | Pyrrolo-quinoxalinone derivatives as antibacterials | GLAXO GROUP LIMITED (GB) | 2010-05-04 | — | — | US | disclosed |
| US-7709483-B2 | Pyrrolo-quinoxalinone derivatives as antibacterials | GLAXO GROUP LIMITED (GB) | 2010-05-04 | — | — | US | disclosed |
| US-20090062265-A1 | Pyrrolo-Quinoxalinone Derivatives as Antibacterials | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20090062265-A1 | Pyrrolo-Quinoxalinone Derivatives as Antibacterials | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20090062265-A1 | Pyrrolo-Quinoxalinone Derivatives as Antibacterials | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| EP-2001887-A1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007115947-A1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062265-A1 | Pyrrolo-Quinoxalinone Derivatives as Antibacterials | NQO2, PPOX, ASNS | KCNH2 2502/4885SLC2A1 4506/4885TOP2A 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.